Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study
Background and Aim Eptinezumab is a quarterly intravenous infusion monoclonal antibody (mAb) with high affinity for calcitonin gene related peptide (CGRP) and a long-lasting mechanism of action. In our retrospective observational study, we sought to investigate the effectiveness and safety of eptine...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Cephalalgia Reports |
| Online Access: | https://doi.org/10.1177/25158163251316809 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582495016583168 |
|---|---|
| author | Alessia Bellotti Caterina Podella Paola Sarchielli |
| author_facet | Alessia Bellotti Caterina Podella Paola Sarchielli |
| author_sort | Alessia Bellotti |
| collection | DOAJ |
| description | Background and Aim Eptinezumab is a quarterly intravenous infusion monoclonal antibody (mAb) with high affinity for calcitonin gene related peptide (CGRP) and a long-lasting mechanism of action. In our retrospective observational study, we sought to investigate the effectiveness and safety of eptinezumab both in mAbs-naïve and mAbs-non responders’ patients. Methods We collected clinical data from electronic charts of 30 migraineurs who underwent six months of eptinezumab treatment; 18 patients had never undergone mAbs-prophylaxis (G1) while 12 had been non-responders to erenumab/galcanezumab (G2). Monthly Headache Days (MHDs), MIDAS, HIT6 and ASC scores were recorded before eptinezumab (T0) and thereafter every three months. Patients were considered responders whenever MHDs reduction was >50% at six months (T2). Results Overall, 25 out of 30 patients (15 in G1 and 10 in G2) were eptinezumab responders (83.3%). Headache frequency (MHDs) at T0 was 12.4 in G1 and 17.0 in G2, while at T2 it was 7.1 in G1 and 8.0 in G2 (p-value < 0.0001). Significant reductions in MIDAS, HIT6 and ASC scores were also observed. No safety concerns were registered. Conclusions Based upon our retrospective observational study, eptinezumab might be effective and safe also for those migraineurs who resulted being non-responders to other anti-CGRP(R) mAbs. |
| format | Article |
| id | doaj-art-15d13f50569b4ac680a5ae90747fc5bb |
| institution | Kabale University |
| issn | 2515-8163 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cephalalgia Reports |
| spelling | doaj-art-15d13f50569b4ac680a5ae90747fc5bb2025-01-29T15:03:59ZengSAGE PublishingCephalalgia Reports2515-81632025-01-01810.1177/25158163251316809Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational studyAlessia Bellotti0Caterina Podella1Paola Sarchielli2 Headache Center, Day Swiss Institute SA, Lugano, Switzerland Headache Center, Day Swiss Institute SA, Lugano, Switzerland Section of Neurology, Department of Medicine and Surgery, , Perugia, ItalyBackground and Aim Eptinezumab is a quarterly intravenous infusion monoclonal antibody (mAb) with high affinity for calcitonin gene related peptide (CGRP) and a long-lasting mechanism of action. In our retrospective observational study, we sought to investigate the effectiveness and safety of eptinezumab both in mAbs-naïve and mAbs-non responders’ patients. Methods We collected clinical data from electronic charts of 30 migraineurs who underwent six months of eptinezumab treatment; 18 patients had never undergone mAbs-prophylaxis (G1) while 12 had been non-responders to erenumab/galcanezumab (G2). Monthly Headache Days (MHDs), MIDAS, HIT6 and ASC scores were recorded before eptinezumab (T0) and thereafter every three months. Patients were considered responders whenever MHDs reduction was >50% at six months (T2). Results Overall, 25 out of 30 patients (15 in G1 and 10 in G2) were eptinezumab responders (83.3%). Headache frequency (MHDs) at T0 was 12.4 in G1 and 17.0 in G2, while at T2 it was 7.1 in G1 and 8.0 in G2 (p-value < 0.0001). Significant reductions in MIDAS, HIT6 and ASC scores were also observed. No safety concerns were registered. Conclusions Based upon our retrospective observational study, eptinezumab might be effective and safe also for those migraineurs who resulted being non-responders to other anti-CGRP(R) mAbs.https://doi.org/10.1177/25158163251316809 |
| spellingShingle | Alessia Bellotti Caterina Podella Paola Sarchielli Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study Cephalalgia Reports |
| title | Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study |
| title_full | Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study |
| title_fullStr | Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study |
| title_full_unstemmed | Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study |
| title_short | Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study |
| title_sort | effectiveness and safety of eptinezumab in anti cgrp r mabs naive and mabs non responders patients a retrospective observational study |
| url | https://doi.org/10.1177/25158163251316809 |
| work_keys_str_mv | AT alessiabellotti effectivenessandsafetyofeptinezumabinanticgrprmabsnaiveandmabsnonresponderspatientsaretrospectiveobservationalstudy AT caterinapodella effectivenessandsafetyofeptinezumabinanticgrprmabsnaiveandmabsnonresponderspatientsaretrospectiveobservationalstudy AT paolasarchielli effectivenessandsafetyofeptinezumabinanticgrprmabsnaiveandmabsnonresponderspatientsaretrospectiveobservationalstudy |